GLP-1R gold rush: Emerging biotechs can challenge market leaders, says GlobalData GlobalData Jan 14, 2025 While mega-cap companies dominate the GLP-1R market and are expected to maintain their stronghold in 2030, three smaller biotechs…
Viking Therapeutics’ obesity drug could become direct competitor to Eli Lilly’s tirzepatide:… EP News Bureau Aug 1, 2024 With promising Phase IIa results and a dual GLP-1/GIP receptor mechanism, VK2735 could soon compete directly with tirzepatide in…
